Your browser doesn't support javascript.
loading
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Moore, Kathleen N; Chambers, Setsuko K; Hamilton, Erika P; Chen, Lee-May; Oza, Amit M; Ghamande, Sharad A; Konecny, Gottfried E; Plaxe, Steven C; Spitz, Daniel L; Geenen, Jill J J; Troso-Sandoval, Tiffany A; Cragun, Janiel M; Rodrigo Imedio, Esteban; Kumar, Sanjeev; Mugundu, Ganesh M; Lai, Zhongwu; Chmielecki, Juliann; Jones, Suzanne F; Spigel, David R; Cadoo, Karen A.
Afiliação
  • Moore KN; Sarah Cannon Research Institute, Nashville, Tennessee. Kathleen-Moore@ouhsc.edu.
  • Chambers SK; Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, Oklahoma.
  • Hamilton EP; The University of Arizona Cancer Center, Tucson, Arizona.
  • Chen LM; Sarah Cannon Research Institute, Nashville, Tennessee.
  • Oza AM; Tennessee Oncology, PLLC, Nashville, Tennessee.
  • Ghamande SA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Konecny GE; Bras Drug Development Program, Princess Margaret Cancer Centre, Toronto, Canada.
  • Plaxe SC; Augusta University, Augusta, Georgia.
  • Spitz DL; UCLA, Los Angeles, California.
  • Geenen JJJ; UC San Diego Health, La Jolla, California.
  • Troso-Sandoval TA; Sarah Cannon Research Institute, Nashville, Tennessee.
  • Cragun JM; Florida Cancer Specialists & Research Institute, Wellington, Florida.
  • Rodrigo Imedio E; Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Kumar S; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mugundu GM; The University of Arizona Cancer Center, Tucson, Arizona.
  • Lai Z; Oncology Global Medicines Development (GMD), AstraZeneca, Cambridge, United Kingdom.
  • Chmielecki J; Oncology Global Medicines Development (GMD), AstraZeneca, Cambridge, United Kingdom.
  • Jones SF; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts.
  • Spigel DR; Translational Medicine, Oncology Research and Development, AstraZeneca, Boston, Massachusetts.
  • Cadoo KA; Translational Medicine, Oncology Research and Development, AstraZeneca, Boston, Massachusetts.
Clin Cancer Res ; 28(1): 36-44, 2022 01 01.
Article em En | MEDLINE | ID: mdl-34645648
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Platina Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Platina Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos